Your browser is no longer supported. Please, upgrade your browser.
Settings
ASLN [NASD]
ASLAN Pharmaceuticals Limited
Index- P/E- EPS (ttm)-0.42 Insider Own- Shs Outstand70.29M Perf Week-4.18%
Market Cap193.30M Forward P/E- EPS next Y-0.51 Insider Trans- Shs Float47.93M Perf Month-22.10%
Income-16.20M PEG- EPS next Q-0.11 Inst Own39.70% Short Float3.17% Perf Quarter-19.83%
Sales- P/S- EPS this Y70.90% Inst Trans- Short Ratio1.71 Perf Half Y32.85%
Book/sh-0.26 P/B- EPS next Y-25.50% ROA-86.30% Target Price- Perf Year58.05%
Cash/sh0.20 P/C13.42 EPS next 5Y- ROE206.60% 52W Range1.26 - 6.75 Perf YTD50.27%
Dividend- P/FCF- EPS past 5Y60.00% ROI- 52W High-59.26% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low118.25% ATR0.23
Employees18 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)38.81 Volatility5.91% 7.88%
OptionableYes Debt/Eq- EPS Q/Q83.60% Profit Margin- Rel Volume0.50 Prev Close2.78
ShortableYes LT Debt/Eq- EarningsMay 11 BMO Payout- Avg Volume890.87K Price2.75
Recom2.30 SMA20-11.23% SMA50-10.98% SMA2000.34% Volume445,699 Change-1.08%
Jul-09-21Initiated Jefferies Buy $8
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Jul-13-21 07:00AM  
Jul-09-21 06:08PM  
09:00AM  
Jun-14-21 07:11AM  
Jun-08-21 09:04AM  
Jun-04-21 09:04AM  
May-25-21 07:30AM  
May-11-21 07:30AM  
May-07-21 07:24AM  
May-05-21 05:22AM  
Apr-30-21 09:24AM  
Apr-22-21 07:51AM  
Apr-14-21 09:38AM  
09:03AM  
Mar-18-21 07:27AM  
Mar-10-21 12:00PM  
Mar-04-21 02:47PM  
Mar-03-21 12:42AM  
Mar-02-21 08:01AM  
Mar-01-21 04:01PM  
08:18AM  
06:00AM  
05:13AM  
Feb-25-21 06:30AM  
Feb-18-21 07:00AM  
Jan-27-21 07:35AM  
Jan-26-21 07:30AM  
Jan-11-21 05:34AM  
Jan-08-21 09:57AM  
Jan-06-21 11:13AM  
09:24AM  
Jan-04-21 09:34AM  
Dec-30-20 11:25AM  
Dec-25-20 12:00PM  
Dec-23-20 10:06AM  
Dec-22-20 10:27AM  
10:22AM  
Dec-21-20 10:13AM  
Dec-10-20 09:40AM  
Dec-03-20 10:04AM  
08:41AM  
Dec-02-20 06:03PM  
03:52PM  
Dec-01-20 10:06AM  
10:04AM  
08:30AM  
Nov-29-20 08:24PM  
Nov-27-20 08:25AM  
Nov-24-20 03:10PM  
03:08PM  
03:07PM  
Nov-19-20 07:22AM  
Nov-18-20 11:24AM  
11:13AM  
Nov-16-20 06:30AM  
Nov-09-20 07:00AM  
Oct-22-20 07:30AM  
Oct-19-20 10:05AM  
Oct-16-20 05:25AM  
Sep-21-20 06:00AM  
Sep-10-20 03:08AM  
Aug-24-20 03:27AM  
Aug-07-20 03:00AM  
Jul-17-20 06:08AM  
Jul-13-20 12:00PM  
08:06AM  
Jun-25-20 08:50AM  
Jun-19-20 05:50PM  
Jun-11-20 12:00PM  
Jun-04-20 09:46PM  
May-11-20 05:34AM  
May-07-20 05:50PM  
Apr-20-20 08:56AM  
Apr-13-20 04:21AM  
Mar-26-20 12:00PM  
Mar-18-20 05:18AM  
Feb-24-20 02:05AM  
Feb-20-20 05:50PM  
Feb-10-20 05:45PM  
Feb-04-20 05:45PM  
Jan-28-20 10:39AM  
Jan-27-20 11:30AM  
Jan-15-20 04:34PM  
08:22AM  
Jan-14-20 08:53AM  
Jan-13-20 12:00PM  
Jan-06-20 12:04PM  
Dec-18-19 09:58AM  
06:57AM  
Dec-05-19 06:22PM  
Dec-03-19 02:29PM  
07:59AM  
01:00AM  
Dec-02-19 01:34PM  
12:50PM  
07:51AM  
02:07AM  
Nov-22-19 08:18AM  
01:30AM  
Nov-11-19 12:36PM  
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.